var data={"title":"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/contributors\" class=\"contributor contributor_credentials\">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/contributors\" class=\"contributor contributor_credentials\">Edward T Ryan, MD, DTMH</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncomplicated falciparum malaria consists of symptomatic <em>Plasmodium falciparum</em> infection with a positive parasitologic test and parasitemia &lt;4 percent, in the absence of symptoms consistent with severe malaria (<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 1</a>).</p><p>Issues related to treatment of uncomplicated falciparum malaria in nonpregnant adults and children will be reviewed here. Issues related to treatment of severe malaria, treatment of malaria in pregnant women, and treatment of non-falciparum malaria are discussed separately. (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women\" class=\"medical medical_review\">&quot;Prevention and treatment of malaria in pregnant women&quot;</a> and <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2656407859\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncomplicated falciparum malaria consists of symptomatic <em>P. falciparum</em> infection with a positive parasitologic test and parasitemia &lt;4 percent, in the absence of symptoms consistent with severe malaria (<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 1</a>). (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p>To establish the diagnosis of malaria, microscopy of blood smears or a rapid diagnostic test (RDT) should be performed. RDTs often can provide the speciation to guide therapy. If the initial diagnostic evaluation is negative, follow-up testing should be performed each day for two more days. (See <a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2952664241\"><span class=\"h1\">PRINCIPLES OF TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to treatment of malaria, including indications for hospitalization, antimalarial selection and parasitemia monitoring are discussed below.</p><p>Patients should be informed that malaria can recrudesce and that repeat evaluation for malaria should be pursued in the event of subsequent febrile episodes. (See <a href=\"#H909816047\" class=\"local\">'Recurrent infection'</a> below.)</p><p>Malaria is a nationally notifiable disease, and all cases should be reported to the state health department.</p><p class=\"headingAnchor\" id=\"H345141709\"><span class=\"h2\">Indications for hospitalization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hospitalization permits clinical observation for tolerance of antimalarial therapy, monitoring for reduction in parasitemia (reflecting efficacy of therapy), and advanced management in the case of progression to severe disease. Hospitalization is appropriate for patients in the following categories, who may deteriorate rapidly [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Young children</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunocompromised patients</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with no acquired immunity (ie, individuals from nonendemic areas)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with hyperparasitemia (4 to 10 percent) but no signs of severe infection; such patients are at increased risk for progression to severe malaria <span class=\"nowrap\">and/or</span> treatment failure and are an important potential source of drug resistance</p><p/><p class=\"headingAnchor\" id=\"H2597737481\"><span class=\"h2\">Antimalarial selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to antimalarial selection is determined by whether infection was acquired in an area with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> sensitivity or resistance and further determined based on local antimalarial drug resistance and government treatment guidelines as well as drug availability and tolerability.</p><p>In general, treatment of uncomplicated malaria consists of oral therapy with a combination of two agents (in the case of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance) or chloroquine monotherapy (in the case of chloroquine sensitivity). The goal of this strategy is to forestall the development of further antimalarial resistance and conserve the antimalarial agents that are presently effective.</p><p>Patients on malaria prophylaxis who develop malaria infection should receive a different medication for treatment.</p><p class=\"headingAnchor\" id=\"H3151847369\"><span class=\"h3\">Chloroquine-sensitive malaria</span></p><p class=\"headingAnchor\" id=\"H1495685656\"><span class=\"h4\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regions with malaria transmission are summarized in the Figure (<a href=\"image.htm?imageKey=ID%2F72797%7EID%2F103385\" class=\"graphic graphic_figure graphicRef72797 graphicRef103385 \">figure 1A-B</a>). Regions with chloroquine-sensitive malaria include Haiti, the Dominican Republic, most regions of the Mid East, and Central America west of the Panama Canal. Additional information summarizing presence of drug resistance by country is available <a href=\"http://www.cdc.gov/malaria/travelers/country_table/a.html&amp;token=Kw0lYaSzYZYCz0dVW5oNq8KoR4uoG6mzz8+OOB1XUAh/Z4MBiCR4qBJWOIK//C5gcj/C7vlu6yJbedKgZrpjew==&amp;TOPIC_ID=5704\" target=\"_blank\" class=\"external\">online</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Among patients for whom chloroquine-sensitive <em>P. falciparum</em> malaria can be predicted with certainty, treatment with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> may be administered. Dosing for administration of chloroquine is outlined in the Table (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a>). (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a>.)</p><p>Treatment for chloroquine-resistant <em>P. falciparum</em> should be administered in the setting of known exposure to a chloroquine-resistant region, unknown prevalence of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance, or uncertain exposure history. (See <a href=\"#H4\" class=\"local\">'Chloroquine-resistant malaria'</a> below.)</p><p class=\"headingAnchor\" id=\"H583734511\"><span class=\"h4\">Reversion of chloroquine resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reappearance of chloroquine-sensitive malaria strains has been described in areas where <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> is no longer routinely used for treatment. In one study including 210 children in Malawi, treatment of uncomplicated malaria with chloroquine was 99 percent effective 12 years after chloroquine was withdrawn due to resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/4\" class=\"abstract_t\">4</a>]. This suggests that, in areas where chloroquine regains effectiveness, the use of chloroquine as a partner drug in combination therapy may be effective.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Chloroquine-resistant malaria</span></p><p class=\"headingAnchor\" id=\"H1146629277\"><span class=\"h4\">Within endemic areas</span></p><p class=\"headingAnchor\" id=\"H1706830252\"><span class=\"h5\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For treatment of uncomplicated <em>P. falciparum</em> malaria (or species not identified) in endemic areas with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance, we are in agreement with the World Health Organization (WHO), which favors first-line therapy with one of the following artemisinin-based combination therapies (ACTs) (<a href=\"image.htm?imageKey=ID%2F107438\" class=\"graphic graphic_table graphicRef107438 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">Artemether-lumefantrine</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Artesunate-amodiaquine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Artesunate-mefloquine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dihydroartemisinin-piperaquine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Artesunate-sulfadoxine-pyrimethamine (SP), in areas with known SP sensitivity</p><p/><p>ACTs have a low side effect profile, are potent against all blood stages (asexual forms) of malaria, and have the most rapid clearance time relative to other antimalarial drugs (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/5\" class=\"abstract_t\">5</a>]. Artemisinins should be administered with a second agent that has a longer half-life than the artemisinin drug to forestall development of artemisinin resistance and to provide an extended duration of drug level to clear parasitemia [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Administration of artemisinins alone would result in recrudescence (treatment failure) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/8\" class=\"abstract_t\">8</a>]. Dosing of ACTs is summarized in the Table (<a href=\"image.htm?imageKey=ID%2F107438\" class=\"graphic graphic_table graphicRef107438 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>].</p><p>No ACT has been proven to be superior to any other; the compounds differ slightly in their stability, oral absorption, bioavailability, and metabolism. Clinical studies evaluating the efficacy of these agents are summarized in the Table (<a href=\"image.htm?imageKey=ID%2F107437\" class=\"graphic graphic_table graphicRef107437 \">table 4</a>). Local drug resistance patterns should inform treatment guidelines. (See <a href=\"#H3733025409\" class=\"local\">'Artemisinin resistance'</a> below.)</p><p>The total artemisinin dose (10 to 12 <span class=\"nowrap\">mg/kg)</span> is given over three days. In areas of artemisinin resistance, a six-day course of treatment is warranted [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/9\" class=\"abstract_t\">9</a>]. A three-day regimen covers two asexual cycles such that only a small fraction of parasites remain for clearance by the partner drug, thus reducing potential for development of resistance to the partner drug. (See <a href=\"#H3733025409\" class=\"local\">'Artemisinin resistance'</a> below.)</p><p>Patients who are not able to tolerate oral medication require initial treatment with rectal or parenteral drug administration until they are able to tolerate oral medication; subsequently, a full three-day course of oral ACT should be administered. The rectal and parenteral regimens are as described separately for treatment of severe malaria. (See <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p>Patients with mild malaria and hyperparasitemia (4 to 10 percent) are at increased risk of treatment failure and warrant close monitoring in a hospital setting if feasible [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H909816047\"><span class=\"h5\">Recurrent infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrence of <em>P. falciparum</em> malaria can result from recrudescence (treatment failure) or reinfection; these may be difficult to distinguish. Treatment failure can occur as a result of drug resistance or inadequate drug exposure (due to underdosing, poor adherence, vomiting, pharmacokinetic factors, or substandard medication).</p><p>In general, treatment failure may be assumed in the setting of lack of resolution of fever and parasitemia or recurrence of these findings within 28 days of treatment; reinfection may be assumed in the setting of fever and parasitemia &gt;28 days following treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>].</p><p>For patients with recurrent infection &le;28 days following treatment for uncomplicated malaria (likely attributable to recrudescence [treatment failure]), we are in agreement with the WHO, which favors treatment with an alternative ACT known to be effective in the region [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>]. Retreatment with the same ACT may be reasonable (particularly in settings where there is no second ACT available); one study noted similar retreatment outcomes between patients retreated the same ACT versus an alternative ACT [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/10\" class=\"abstract_t\">10</a>].</p><p>For patients with recurrent infection &gt;28 days following treatment for uncomplicated malaria (likely attributable to reinfection), we are in agreement with the WHO, which favors treatment with a first-line ACT [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1\" class=\"abstract_t\">1</a>]. However, reuse of <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> within 60 days of initial treatment has been associated with an increased risk for neuropsychiatric reactions; therefore, if mefloquine was administered during initial treatment, an alternative regimen should be used.</p><p>When possible, suspected treatment failure should be confirmed parasitologically, with microscopy or rapid diagnostic tests (RDTs). RDTs based on lactate dehydrogenase are preferred for diagnosis of treatment failure, since RDTs based on histidine-rich protein 2 may remain positive for weeks after initial infection, in the absence of recrudescence. (See <a href=\"topic.htm?path=diagnosis-of-malaria#H23056321\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;, section on 'Rapid diagnostic tests'</a>.)</p><p class=\"headingAnchor\" id=\"H4118771064\"><span class=\"h5\">Reducing transmissibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gametocytes may persist in the blood after successful treatment of infection (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 2</a>); they are not harmful to the patient but serve as a source of ongoing transmission. <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">Artemether-lumefantrine</a> has been shown to be superior to non-artemisinin antimalarial drugs in reducing gametocytemia [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/11\" class=\"abstract_t\">11</a>]. <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> has activity against mature gametocytes but no effect on blood-stage parasites.</p><p>To further reduce transmissibility of treated <em>P. falciparum</em> infection in endemic areas with low transmission, we are in agreement with the WHO, which favors administration of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> (0.25 <span class=\"nowrap\">mg/kg</span> single dose) on the first day of malaria treatment to nonpregnant adults and children &ge;6 months [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/1,7,12-18\" class=\"abstract_t\">1,7,12-18</a>]. However, primaquine should be avoided in pregnant women and infants &lt;6 months of age given the particular vulnerability of these patient groups.</p><p><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> can cause hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency; however, G6PD testing is not required for patients receiving primaquine for reducing transmissibility given the relatively low dose for this indication. In one study including 274 Senegalese patients with mild malaria randomized to ACT plus primaquine (0.25 <span class=\"nowrap\">mg/kg,</span> single dose) versus ACT alone, the mean reduction in hemoglobin at day 7 was equivalent [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/19\" class=\"abstract_t\">19</a>]. Among 54 patients with G6PD deficiency, the drop in hemoglobin was 0.63 <span class=\"nowrap\">g/dL</span> greater in those who received primaquine than in those who received an ACT alone. (See <a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency#H7\" class=\"medical medical_review\">&quot;Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency&quot;, section on 'Inciting drugs, foods, illnesses'</a>.)</p><p class=\"headingAnchor\" id=\"H3733025409\"><span class=\"h5\">Artemisinin resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Artemisinin resistance has been observed; use of artemisinin monotherapy in the region is the most likely cause, as discussed below.</p><p>A six-day course of ACT (standard dosing) appears to be efficacious for treatment uncomplicated <em>P. falciparum </em>malaria in areas where standard three-day treatments are failing [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/9\" class=\"abstract_t\">9</a>]. No improvement in parasite clearance has been observed with increasing the artemisinin dose or with splitting the dose [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/20\" class=\"abstract_t\">20</a>].</p><p>The result of a malaria blood smear on day 3 of treatment with an ACT may be a useful screening tool for presence of artemisinin resistance. Artemisinin resistance is unlikely if the proportion of patients with parasite density &lt;100,000 <span class=\"nowrap\">parasites/microL</span> is less than 3 percent following a three-day course of ACT therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Artemisinin resistance was initially observed in Southeast Asia and has also been observed in South America; ongoing surveillance will be needed to understand the global epidemiology of artemisinin resistance:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Southeast Asia</strong> &ndash; In a region of western Cambodia with a long history of artemisinin monotherapy, <em>P. falciparum</em> parasites have been found to have prolonged parasite clearance times relative to parasites in northwestern Thailand (where artemisinins have been used in combination therapy) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/9,22-24\" class=\"abstract_t\">9,22-24</a>]. Among 80 patients (40 in western Cambodia and 40 in northwestern Thailand) randomized to treatment with oral <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> monotherapy or combination therapy with artesunate and <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, the median parasite clearance time was significantly higher in the Cambodian patients (84 versus 48 hours) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/23\" class=\"abstract_t\">23</a>]. This was not correlated with a change in in vitro drug inhibition studies but nevertheless suggests the development of parasite populations that have decreased in vivo sensitivity to artemisinins. Subsequently, evidence of prolonged parasite clearance time in the setting of artemisinin use has been described in western Thailand; this is believed to have developed locally rather than by importation of resistant parasites from Cambodia, since no genotypes in Thailand matched those in western Cambodia [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/25\" class=\"abstract_t\">25</a>].</p><p/><p class=\"bulletIndent1\">In 2014, <em>P. falciparum</em> resistance to artemisinin was noted to be prevalent across Southeast Asia and was observed to occur in association with mutations in the parasite's kelch protein gene on chromosome 13 (<em>kelch13</em>) [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/9,26\" class=\"abstract_t\">9,26</a>]. The prevalence of artemisinin K13 propeller mutations varies greatly by region; rates as high as 47 percent in parts of Myanmar have been observed. Spread of artemisinin-resistant parasites is due to transmission of single clones across regions; however, individual populations of parasites can develop artemisinin resistance independently, which may make containment of artemisinin-resistant parasites more challenging [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/27-29\" class=\"abstract_t\">27-29</a>]. One report from China noted delayed parasite clearance following artemisinin treatment of infection due to <em>P. falciparum</em> caused by organisms harboring a single K13 mutation [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/30\" class=\"abstract_t\">30</a>].</p><p/><p class=\"bulletIndent1\">In 2016, a prospective study of dihydroartemisinin-piperaquine including 81 Cambodian patients in a region with established artemisinin resistance noted parasite recrudescence in 46 percent of cases. The parasites had the artemisinin resistance&ndash;associated <em>kelch13</em> mutations but also had increased the half maximal inhibitory concentration (IC<sub>50</sub>) to piperaquine, suggesting that resistance in the partner drug was also an important component of clinical resistance to ACTs [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/17\" class=\"abstract_t\">17</a>]. Treatment of malaria in this region should consist of <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> plus <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>South America</strong> &ndash; In South America, independent emergence of a <em>kelch13 </em>mutant allele, which has been associated with artemisinin clinical resistance in Southeast Asia, has been described in Guyana [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/31\" class=\"abstract_t\">31</a>]. Continued molecular surveillance and assessment of the therapeutic efficacy of artemisinin combination therapy regimens are warranted.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sub-Saharan Africa</strong> &ndash; In sub-Saharan Africa, no molecular evidence of artemisinin resistance was identified in a study including examination of 14 pools of <em>P. falciparum</em> gDNA from 14 study sites between 2002 and 2011 for mutations in the K13 propeller gene; no artemisinin-associated resistance mutations were identified [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/32\" class=\"abstract_t\">32</a>]. A subsequent study including 1212 samples from 12 countries noted no K13-propeller mutations previously reported in Southeast Asia but did detect 22 unique mutations, of which 7 were non-synonymous [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/33\" class=\"abstract_t\">33</a>]. Whether these mutations confer artemisinin resistance is unknown. Ongoing surveillance will be needed to identify emergence of artemisinin resistance in Africa.</p><p/><p class=\"bulletIndent1\">A worldwide analysis of K13 propeller mutations noted no evidence of artemisinin resistance outside of Southeast Asia and China; many African mutations appeared to be neutral, and the common African allele A578S was not associated with clinical or in vitro resistance to artemisinin [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"headingAnchor\" id=\"H3448645223\"><span class=\"h4\">Outside endemic areas</span></p><p class=\"headingAnchor\" id=\"H727122180\"><span class=\"h5\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncomplicated malaria can progress to severe illness in nonimmune individuals within hours to days, so it is important that therapy be initiated promptly and that patients be hospitalized if possible.</p><p>There are a number of regimens available for treatment of uncomplicated <em>P. falciparum</em> malaria (or species not identified) acquired in areas with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance; therapeutic options available within and outside endemic may differ. Regimens include (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F107438\" class=\"graphic graphic_table graphicRef107438 \">table 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Artemisinin combination therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Quinine-based regimens</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a></p><p/><p>The preferred regimens consist of an ACT or <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a>. Late treatment failures with <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a> have been reported in nonimmune travelers, some with subtherapeutic lumefantrine concentrations [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/35\" class=\"abstract_t\">35</a>]. The effectiveness of artemether-lumefantrine has been correlated with body weight (for body weight &le;65 kg, effectiveness was 100 percent [95% CI 66 to 100 percent]; for body weight &gt;65 kg, effectiveness was 90 percent [95% CI 79 to 96 percent]). (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a>.)</p><p>Issues related to ACTs are discussed further above. (See <a href=\"#H1706830252\" class=\"local\">'Clinical approach'</a> above.)</p><p><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a> is a well-tolerated and effective treatment for uncomplicated falciparum malaria in patients who were not taking this agent for prophylaxis during the period of exposure to malaria. Its use in resource-limited settings is limited by cost. Studies of atovaquone-proguanil conducted in Southeast Asia, South America, and Africa have demonstrated cure rates of &gt;95 percent with no severe adverse side effects [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/36,37\" class=\"abstract_t\">36,37</a>]. Several studies have demonstrated higher efficacy of the atovaquone-proguanil combination over chloroquine-based therapy and <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/38,39\" class=\"abstract_t\">38,39</a>].</p><p>An alternative regimen consists of <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> sulfate administered in combination with <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>. Quinine-based regimens are effective but are less preferable due to bitter taste, cinchonism (reversible tinnitus and reversible high-tone hearing loss), and gastrointestinal side effects [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Doxycycline and tetracycline are preferred over clindamycin as quinine partner drugs since they are associated with greater efficacy. For infections acquired in Southeast Asia, treatment consists of quinine (seven days) plus doxycycline, tetracycline, or clindamycin (seven days). For infections acquired outside Southeast Asia, treatment consists of quinine (three days) plus doxycycline, tetracycline, or clindamycin (seven days).</p><p>Mefloquine-based regimens should be used only when the above regimens are not available; <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> has been associated with neuropsychiatric effects and resistance in some areas [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/43\" class=\"abstract_t\">43</a>]. Outside the Thai&ndash;Myanmar&ndash;Cambodia area, mefloquine cures 90 to 95 percent of <em>P. falciparum</em> malaria. Within the Thai&ndash;Myanmar&ndash;Cambodia area, mefloquine cure rates have dropped to 60 percent due to resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/44-46\" class=\"abstract_t\">44-46</a>].</p><p class=\"headingAnchor\" id=\"H925848088\"><span class=\"h5\">Recrudescence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with recrudescence (treatment failure) outside endemic areas, treatment should consist of an alternative antimalarial regimen in case of drug resistance to the initial regimen (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F107438\" class=\"graphic graphic_table graphicRef107438 \">table 3</a>).</p><p>In addition, evaluation for coinfection with <em>P. vivax</em> or <em>P. ovale</em> should be pursued, as these species can cause relapse due to their hypnozoite stage. Identification of coinfection with these species requires treatment of the asexual stage as well as <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> for treatment of hypnozoites. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3788067485\"><span class=\"h2\">Monitoring parasitemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Parasitemia should be monitored during treatment to confirm adequate response to therapy. Daily blood smears are appropriate to document declining parasite density until no parasitemia is detected or until seven days of treatment have been completed [<a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=diagnosis-of-malaria#H4943905\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;, section on 'Parasite density monitoring'</a>.)</p><p class=\"headingAnchor\" id=\"H3759000255\"><span class=\"h1\">INVESTIGATIONAL ANTIMALARIAL DRUGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Investigational antimalarial drugs are discussed separately. (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview#H18\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;, section on 'Investigational drugs'</a>.)</p><p class=\"headingAnchor\" id=\"H2686383343\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Malaria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uncomplicated falciparum malaria consists of symptomatic <em>Plasmodium falciparum</em> infection with a positive parasitologic test and parasitemia &lt;4 percent, in the absence of symptoms consistent with severe malaria (<a href=\"image.htm?imageKey=ID%2F107439\" class=\"graphic graphic_table graphicRef107439 \">table 1</a>). (See <a href=\"#H2656407859\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The approach to antimalarial selection is guided by whether infection was acquired in an area with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> sensitivity or resistance and further determined based on local availability of therapeutic agents. Patients on malaria prophylaxis who develop malaria infection should receive a different medication for treatment. (See <a href=\"#H2597737481\" class=\"local\">'Antimalarial selection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients for whom chloroquine-sensitive <em>P. falciparum</em> malaria can be predicted with certainty, we suggest treatment with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H3151847369\" class=\"local\">'Chloroquine-sensitive malaria'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment for chloroquine-resistant <em>P. falciparum</em> should be administered in the setting of known exposure to a chloroquine-resistant region, unknown prevalence of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance, or uncertain exposure history. (See <a href=\"#H4\" class=\"local\">'Chloroquine-resistant malaria'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For treatment of uncomplicated <em>P. falciparum</em> malaria (or species not identified) with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance in endemic areas, we suggest treatment with artemisinin combination therapy (ACT) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Dosing is summarized in the Table (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a>). (See <a href=\"#H1146629277\" class=\"local\">'Within endemic areas'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For treatment of uncomplicated <em>P. falciparum</em> malaria (or species not identified) with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance outside endemic areas, we suggest treatment with ACT or <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). For individuals &gt;65 kg treated with an ACT, we suggest use of an agent other than <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Dosing is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F72019\" class=\"graphic graphic_table graphicRef72019 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F107438\" class=\"graphic graphic_table graphicRef107438 \">table 3</a>). (See <a href=\"#H3448645223\" class=\"local\">'Outside endemic areas'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Parasitemia should be monitored during treatment to confirm adequate response to therapy. Daily blood smears are appropriate to document declining parasite density until no parasitemia is detected or until seven days of treatment have been completed. (See <a href=\"#H3788067485\" class=\"local\">'Monitoring parasitemia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent <em>P. falciparum</em> malaria infection can result from recrudescence (treatment failure) or reinfection; these may be difficult to distinguish. (See <a href=\"#H909816047\" class=\"local\">'Recurrent infection'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In general, treatment failure may be assumed in the setting of lack of resolution of fever and parasitemia (or recurrence of these findings) within 28 days of treatment for uncomplicated malaria; for such patients, we suggest therapy with an alternative ACT known to be effective in the region (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In general, reinfection may be assumed in the setting of fever and parasitemia &gt;28 days following treatment for uncomplicated malaria; for such patients, we suggest treatment with a first-line ACT (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with recrudescence outside endemic areas, treatment should consist of an alternative antimalarial regimen, in case of drug resistance to the initial regimen. In addition, evaluation for coinfection with <em>P. vivax</em> or <em>P. ovale</em> should be pursued, as these species can cause relapse due to their hypnozoite stage. Identification of coinfection with these species requires treatment of the asexual stage as well as <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> for treatment of hypnozoites. (See <a href=\"#H3448645223\" class=\"local\">'Outside endemic areas'</a> above and <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>To reduce transmissibility of treated <em>P. falciparum</em> infection in endemic areas with low transmission, we suggest administration of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> (0.25 <span class=\"nowrap\">mg/kg</span> single dose) on the first day of malaria treatment to nonpregnant adults and children &ge;6 months (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Primaquine should be avoided in pregnant women and infants &lt;6 months of age. (See <a href=\"#H4118771064\" class=\"local\">'Reducing transmissibility'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on September 10, 2015).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Treatment Guidelines: Treatment of Malaria (Guidelines for Clinicians), 2013. http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf (Accessed on September 10, 2015).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Malaria Information and Prophylaxis, by Country [A]. http://www.cdc.gov/malaria/travelers/country_table/a.html (Accessed on March 21, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/4\" class=\"nounderline abstract_t\">Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006; 355:1959.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/5\" class=\"nounderline abstract_t\">Newton P, White N. Malaria: new developments in treatment and prevention. Annu Rev Med 1999; 50:179.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/6\" class=\"nounderline abstract_t\">Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011; 52:612.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/7\" class=\"nounderline abstract_t\">Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/8\" class=\"nounderline abstract_t\">Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/9\" class=\"nounderline abstract_t\">Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/10\" class=\"nounderline abstract_t\">Mavoko HM, Nabasumba C, da Luz RI, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health 2017; 5:e60.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/11\" class=\"nounderline abstract_t\">Ippolito MM, Johnson J, Mullin C, et al. The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis. Clin Infect Dis 2017; 65:486.</a></li><li class=\"breakAll\">World Health Organization. Updated WHO Policy Recommendation (October 2012): Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. WHO, Geneva 2012. http://www.who.int/malaria/pq_updated_policy_recommendation_en_102012.pdf (Accessed on March 05, 2013).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/13\" class=\"nounderline abstract_t\">Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013; 56:685.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/14\" class=\"nounderline abstract_t\">Lawpoolsri S, Klein EY, Singhasivanon P, et al. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Malar J 2009; 8:159.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/15\" class=\"nounderline abstract_t\">Graves PM, Gelband H, Garner P. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2015; :CD008152.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/16\" class=\"nounderline abstract_t\">White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012; 11:418.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/17\" class=\"nounderline abstract_t\">Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/18\" class=\"nounderline abstract_t\">Lin JT, Ubalee R, Lon C, et al. Microscopic Plasmodium falciparum Gametocytemia and Infectivity to Mosquitoes in Cambodia. J Infect Dis 2016; 213:1491.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/19\" class=\"nounderline abstract_t\">Tine RC, Sylla K, Faye BT, et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. Clin Infect Dis 2017; 65:535.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/20\" class=\"nounderline abstract_t\">Das D, Tripura R, Phyo AP, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 2013; 56:e48.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/21\" class=\"nounderline abstract_t\">Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/22\" class=\"nounderline abstract_t\">Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/23\" class=\"nounderline abstract_t\">Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/24\" class=\"nounderline abstract_t\">Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/25\" class=\"nounderline abstract_t\">Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/26\" class=\"nounderline abstract_t\">Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015; 15:683.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/27\" class=\"nounderline abstract_t\">Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015; 211:670.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/28\" class=\"nounderline abstract_t\">Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015; 15:415.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/29\" class=\"nounderline abstract_t\">Nyunt MH, Hlaing T, Oo HW, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis 2015; 60:1208.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/30\" class=\"nounderline abstract_t\">Huang F, Takala-Harrison S, Jacob CG, et al. A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. J Infect Dis 2015; 212:1629.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/31\" class=\"nounderline abstract_t\">Chenet SM, Akinyi Okoth S, Huber CS, et al. Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana. J Infect Dis 2016; 213:1472.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/32\" class=\"nounderline abstract_t\">Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015; 211:680.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/33\" class=\"nounderline abstract_t\">Kamau E, Campino S, Amenga-Etego L, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2015; 211:1352.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/34\" class=\"nounderline abstract_t\">M&eacute;nard D, Khim N, Beghain J, et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med 2016; 374:2453.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/35\" class=\"nounderline abstract_t\">Sond&eacute;n K, Wyss K, Jovel I, et al. High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clin Infect Dis 2017; 64:199.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/36\" class=\"nounderline abstract_t\">Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/37\" class=\"nounderline abstract_t\">de Alencar FE, Cerutti C Jr, Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997; 175:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/38\" class=\"nounderline abstract_t\">Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999; 179:1587.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/39\" class=\"nounderline abstract_t\">Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60:526.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/40\" class=\"nounderline abstract_t\">Pasvol G, Newton CR, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991; 45:702.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/41\" class=\"nounderline abstract_t\">Stanley J. Malaria. Emerg Med Clin North Am 1997; 15:113.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/42\" class=\"nounderline abstract_t\">Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 1992; 339:369.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/43\" class=\"nounderline abstract_t\">Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42:415.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/44\" class=\"nounderline abstract_t\">Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992; 339:821.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/45\" class=\"nounderline abstract_t\">Luxemburger C, ter Kuile FO, Nosten F, et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88:213.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/46\" class=\"nounderline abstract_t\">Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children/abstract/47\" class=\"nounderline abstract_t\">Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5704 Version 43.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2656407859\" id=\"outline-link-H2656407859\">DIAGNOSIS</a></li><li><a href=\"#H2952664241\" id=\"outline-link-H2952664241\">PRINCIPLES OF TREATMENT</a><ul><li><a href=\"#H345141709\" id=\"outline-link-H345141709\">Indications for hospitalization</a></li><li><a href=\"#H2597737481\" id=\"outline-link-H2597737481\">Antimalarial selection</a><ul><li><a href=\"#H3151847369\" id=\"outline-link-H3151847369\">- Chloroquine-sensitive malaria</a><ul><li><a href=\"#H1495685656\" id=\"outline-link-H1495685656\">Clinical approach</a></li><li><a href=\"#H583734511\" id=\"outline-link-H583734511\">Reversion of chloroquine resistance</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">- Chloroquine-resistant malaria</a><ul><li><a href=\"#H1146629277\" id=\"outline-link-H1146629277\">Within endemic areas</a><ul><li><a href=\"#H1706830252\" id=\"outline-link-H1706830252\">- Clinical approach</a></li><li><a href=\"#H909816047\" id=\"outline-link-H909816047\">- Recurrent infection</a></li><li><a href=\"#H4118771064\" id=\"outline-link-H4118771064\">- Reducing transmissibility</a></li><li><a href=\"#H3733025409\" id=\"outline-link-H3733025409\">- Artemisinin resistance</a></li></ul></li><li><a href=\"#H3448645223\" id=\"outline-link-H3448645223\">Outside endemic areas</a><ul><li><a href=\"#H727122180\" id=\"outline-link-H727122180\">- Clinical approach</a></li><li><a href=\"#H925848088\" id=\"outline-link-H925848088\">- Recrudescence</a></li></ul></li></ul></li></ul></li><li><a href=\"#H3788067485\" id=\"outline-link-H3788067485\">Monitoring parasitemia</a></li></ul></li><li><a href=\"#H3759000255\" id=\"outline-link-H3759000255\">INVESTIGATIONAL ANTIMALARIAL DRUGS</a></li><li><a href=\"#H2686383343\" id=\"outline-link-H2686383343\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5704|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/72797\" class=\"graphic graphic_figure\">- Malaria map &ndash; Western Hemisphere</a></li><li><a href=\"image.htm?imageKey=ID/103385\" class=\"graphic graphic_figure\">- Malaria map &ndash; Eastern Hemisphere</a></li><li><a href=\"image.htm?imageKey=ID/79113\" class=\"graphic graphic_figure\">- Malaria life cycle drug targets</a></li></ul></li><li><div id=\"ID/5704|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/107439\" class=\"graphic graphic_table\">- Criteria severe falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/72019\" class=\"graphic graphic_table\">- Rx uncomplicated falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/107438\" class=\"graphic graphic_table\">- ACT regimens uncomplicated falciparum malaria</a></li><li><a href=\"image.htm?imageKey=ID/107437\" class=\"graphic graphic_table\">- Clinical trials of ACTs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">Antimalarial drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency\" class=\"medical medical_review\">Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">Diagnosis of malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-malaria-in-pregnant-women\" class=\"medical medical_review\">Prevention and treatment of malaria in pregnant women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-malaria\" class=\"medical medical_society_guidelines\">Society guideline links: Malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">Treatment of severe malaria</a></li></ul></div></div>","javascript":null}